Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).

ABSTRACT:

Introduction

Multiple sclerosis (MS) typically requires life-long management with disease-modifying therapies (DMTs). Many DMTs require regular self-injection, and can be associated with injection site reactions, pain, and needle/injection phobia-but these can be addressed by improvements in autoinjector design. The aim of this study was to investigate patient satisfaction and preference for BETACONNECT™ (Bayer Pharma AG), a novel interferon beta-1b autoinjector.

Methods

Patients in Germany performing self-injections using BETACONNECT took part in the study. Data were collected through an online 15-min structured survey. Participants rated their experience with BETACONNECT on a 6-point scale and those satisfied with BETACONNECT were asked to describe the reason using a free-

SUBMITTER: Ziemssen T 

PROVIDER: S-EPMC4685867 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature